Fulcrum Therapeutics, Inc. (FULC)
$3.68-1.87%Close
SELLBEAR · day 12
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $199M
- Beta
- 3.00
- P/E (TTM)
- -3.04
- Short % float
- 14.81%
- Days to cover
- 4.5
- SI change
- -1.2%
- 1W
- -0.27%
- 1M
- -2.90%
- vs SPY 1W
- -0.13%
- vs SPY 1M
- -5.41%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 13
- VALUE
- 11
- GROWTH
- 47
- GARP
- 5
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-17.1%
REV YoY-
ROE-28.5%
EPS YoY-
ROA-26.2%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-3.04
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B0.90
P/FCF-
EV/EBITDA-3.07
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E1.70
ALTMAN Z-
CURR RATIO31.35
ND/EBITDA-
BETA3.00
Company news
FAQ
- What is LOPJLB’s current signal on FULC?
- LOPJLB’s latest quantitative signal on Fulcrum Therapeutics, Inc. (FULC) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is FULC in?
- Fulcrum Therapeutics, Inc. (FULC) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does Fulcrum Therapeutics, Inc. (FULC) do?
- Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered f…